Janus kinase inhibitors

Optimizing Long-Term Management in Moderate-to-Severe Atopic Dermatitis: Real-World Evidence on 24-Week Abrocitinib Tapering Strategies

This article reviews a retrospective study evaluating the feasibility and outcomes of a 24-week abrocitinib tapering regimen in moderate-to-severe atopic dermatitis, comparing dose reduction versus interval extension approaches and their im